Therapeutic Use of Adipose-Derived Stromal Cells in a Murine Model of Acute Pancreatitis
No specific therapy exists for acute pancreatitis (AP), and current treatment remains entirely supportive. Adipose stem cells (ASCs) have significant immunomodulatory and regenerative activities. We hypothesized that systemic administration of ASCs would mitigate inflammation in AP.
AP was induced in mice by 6 hourly intraperitoneal injections of cerulein. Twenty-four hours after AP induction, mice were randomized into four systemic treatment groups: sham group (no acute pancreatitis), vehicle, human ASCs, and human ASC–conditioned media. Mice were sacrificed at 48 h, and blood and organs were collected and analyzed. Pancreatic injury was quantified histologically using a published score (edema, inflammation, and necrosis). Pancreatic inflammation was also studied by immunohistochemistry and PCR.
When using IV infusion of Hoechst-labeled ASCs, ASCs were found to localize to inflamed tissues: lungs and pancreas. Mice treated with ASCs had less severe AP, as shown by a significantly decreased histopathology score (edema, inflammation, and necrosis) (p = 0.001). ASCs infusion polarized pancreatic macrophages toward an anti-inflammatory M2 phenotype. ASC-conditioned media reduced pancreatic inflammation similarly to ASCs only, highlighting the importance of ASCs secreted factors in modulating inflammation.
Intravenous delivery of human ASCs markedly reduces pancreatic inflammation in a murine model of AP ASCs which represent an effective therapy for AP.
KeywordsAcute pancreatitis Murine model Treatment Adipose stem cells
This work was supported by the 2016–2017 International Hepato-Pancreato-Biliary Association (IHPBA) Kenneth Warren Fellowship.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 29.Álvaro-Gracia JM, Jover JA, García-Vicuña R et al. Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann. Rheum. Dis. 2016;76:196–202.PubMedCrossRefGoogle Scholar
- 32.Watanabe O, Baccino FM, Steer ML, Meldolesi J. Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol. 1984;246:457–67.Google Scholar
- 36.Website: https://www.sigmaaldrich.com/catalog/product/sigma/c9026?lang=en®ion=US; last accessed 05/14/2019
- 56.Maatman TK, Mahajan S, Roch AM et al. High rates of readmission in necrotizing pancreatitis: Natural history of opportunity for improvement? J Gastrointest Surg 2019Google Scholar
- 60.Tran DD, Oe PL, de Fijter CW et al. Acute renal failure in patients with acute pancreatitis: prevalence, risk factors, and outcome. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1993;8:1079–84.Google Scholar